Innovative Nanobody-Based Immunoconjugate Targeting CD274 and TGF-β Receptor for Next-Generation Cancer Therapy

VHH-P621 is a humanized single-domain antibody immunoconjugate designed to precisely target the CD274 molecule (CD274) and the transforming growth factor (TGF)-beta receptor. Utilizing advanced engineering, VHH-P621 features a nanobody architecture C-terminally fused, via a specific linker, to a mutated form of the TGF-beta receptor. Currently in the Biological Testing stage, this program brings forward a novel dual-target approach with the potential to address multiple mechanisms implicated in cancer pathogenesis. VHH-P621 harnesses innovative molecular design to expand the therapeutic landscape for cancer treatment through selective immune modulation.

Licensing Opportunity

VHH-P621 is available for out-licensing and strategic collaboration. We welcome industry partners interested in advancing this unique dual-target nanobody immunoconjugate for innovative cancer therapy.

Development Phase

Modality

VHH-P621 represents a novel immunoconjugate therapy incorporating a humanized nanobody—a single-domain antibody—specifically targeting CD274, fused to a modified TGF-β receptor domain via a linking peptide. Expressed in CHO-K1 cells, the nanobody structure offers distinct advantages, including small molecular size, improved tissue penetration, robust stability, and strong antigen-binding affinity compared to conventional IgG antibodies. The modular design enables precise targeting of tumor microenvironment components, facilitating effective blockade of immune evasion and suppression mechanisms in cancer. The molecular compactness and versatility of the nanobody format enhance its suitability for advanced oncology applications in solid and hematologic malignancies.

Target

CD274 and TGF-β receptor are membrane-associated proteins with critical roles in cancer immunology. CD274, an immune checkpoint molecule expressed on tumor cells and antigen-presenting cells, inhibits T-cell activity, contributing to immune escape. TGF-β receptor is broadly found on diverse cell types and regulates cell proliferation, differentiation, and immune responses within the tumor microenvironment. Both CD274 and TGF-β receptor are essential for tumor immune evasion and progression. Targeting CD274 and TGF-β receptor disrupts multiple pro-tumorigenic signaling pathways, making them highly relevant and validated targets for cancer therapy. VHH-P621's dual specificity for CD274 and TGF-β receptor offers strategic value for overcoming compensatory immune and stromal suppression mechanisms, thereby enhancing anti-tumor responses and broadening the scope of next-generation immunotherapies.

Mechanism of Action

VHH-P621 exerts its function through simultaneous blockade of CD274 and inhibition of TGF-β receptor-mediated signaling pathways. By binding to CD274, the nanobody component interrupts immune checkpoint signaling, restoring cytotoxic T-cell activity against tumor cells. The fused TGF-β receptor domain acts as a decoy, sequestering TGF-β ligands and mitigating their immunosuppressive and pro-tumorigenic actions within the tumor microenvironment. This dual-action mechanism not only reactivates anti-tumor immunity but also targets key stromal drivers of cancer progression. The nanobody platform, exemplified by VHH-P621, provides a flexible foundation for further therapies, including antibody-drug conjugates and multispecific modalities, offering strong potential for broad oncology applications.

Cancer

Cancer comprises a diverse group of diseases characterized by uncontrolled cell growth and the potential for local invasion and distant metastasis. Globally, cancer remains a leading cause of death, with increasing incidence due to population aging and growth. Standard-of-care therapies encompass surgery, chemotherapy, radiation, targeted molecular agents, and immunotherapies. However, resistance development, disease recurrence, and limited responses in certain patient subpopulations highlight significant unmet clinical needs. There is a growing focus on combination strategies and novel immune-based approaches to overcome tumor heterogeneity and microenvironmental barriers. VHH-P621’s targeted inhibition of both CD274 and TGF-β receptor addresses critical pathways involved in immune evasion and tumor progression, offering the potential for enhanced efficacy and durable anti-cancer responses where conventional therapies often fail.